Rahsaan W. Thompson - 24 Feb 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Chief Legal Officer
Issuer ticker: LYEL
Reported as of: 24 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Feb 2023, 17:15:29 UTC
Prior SEC filing: 12 Oct 2022
Next SEC filing: 25 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Hector Casab, as Attorney-in-Fact

Key filing fact

Rahsaan W. Thompson filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 28 Feb 2023.

Key facts

This page summarizes Rahsaan W. Thompson's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2023, 17:15.

Change

Previous filing in this sequence was filed on 12 Oct 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +245,000
Change %
Price: $0.000000
Shares after: 245,000
Date: 24 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 245,000
Exercise price: $2.13
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.